Introduction
Mantle cell lymphoma (MCL) accounts for 5-10% of all non-Hodgkin lymphomas and has an aggressive clinical course. 1 Median survival is approximately 3 years, with few long-term survivors. 1 Virtually all cases of MCL contain a t(11;14)(q13;q32) translocation, which places the cyclin D1 gene under the transcriptional control of the immunoglobulin heavy chain promoter. 1 This translocation results in the overexpression of cyclin D1, which phosphorylates the retinoblastoma protein leading to unrestrained proliferation. 2 Interestingly, transgenic mouse models of cyclin D1 overexpression alone do not recapitulate an MCL phenotype. 3, 4 Indeed, comparative genomic hybridization (CGH) and chromosomal banding studies have identified many additional genetic aberrations in MCL. 5, 6 In particular, the pro-apoptotic BCL-2 family member BIM showed biallelic deletion in 5 of 12 MCL cell lines and loss of expression in 7 of 22 patient samples by tissue microarray analysis. 5 These data suggest that BIM may function as a critical tumor suppressor, whose loss in the context of cyclin D1 overexpression, may contribute to the pathogenesis of MCL.
Apoptotic deregulation is a prominent feature of MCL. For example, in addition to loss of the pro-apoptotic BH3-only protein BIM, overexpression of anti-apoptotic BCL-2 family members is also common. [7] [8] [9] [10] High-level expression of BCL-2, BCL-X L and MCL-1 has been documented in a variety of MCL cell lines. [7] [8] [9] [10] Moreover, in primary specimens, BCL-2 overexpression is seen in almost 97% of cases 11 with 15% showing specific genomic gains or amplifications at the BCL-2 locus. 12 Overexpression of BCL-X L has also been reported in MCL cells, and linked to constitutive activation of the NFkB pathway. 13 High expression levels of MCL-1 correlate with high-grade morphology
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14 Several studies have implicated interactions between cyclin D1 and BAX or BCL-2 in MCL pathophysiology. 12, 15 These findings highlight that BCL-2 family deregulation may serve as a critical control point for MCL pathogenesis and a potential opportunity for therapeutic intervention using pharmacologic modulators of the pathway. 16, 17 Nevertheless, genetic proof of a direct, collaborative role between cyclin D1 expression and BCL-2 family deregulation in the genesis of MCL has not been established.
The development of an MCL mouse model that reflects the human pathophysiology of the disease has been a longstanding challenge. Overexpression of cyclin D1 alone not only fails to produce lymphoproliferative disease, but also results in little to no alteration in B-or T-cell development. 3, 4 In combination with transgenic overexpression of N-myc or C-myc, cyclin D1 accelerates the formation of B cell lymphomas, but these tumors are more similar to those produced in mice engineered to overexpress Myc alone. 3, 4 Moreover, overexpression or rearrangement of Myc is infrequent in MCL, occurring only in the uncommon blastoid variant. 18 Overexpression of a mutant cyclin D1 that is constitutively nuclear is sufficient to produce B cell lymphomas by 13-14 months of age. However, these tumors also manifest blastoid morphology with high levels of Myc expression. 19 In addition, cyclin D1 mutations that result in constitutive nuclear expression are rare in human MCL. 20 
Methods

Mice
The mouse cyclin D1 cDNA (a kind gift from P. Scizinski, Dana-Farber Cancer Institute) was cloned into the pBluescript II vector, which contains a 1 kb fragment of the mouse variable chain enhancer and promoter (pEμ) and a 1.6 Kb fragment of the human β-globin gene to provide introns and the polyadenylation signal sequence (a kind gift from F. Alt, Children's Hospital Boston). Insert DNA, released by BssHII digestion, was purified and introduced by pronuclear injection into oocytes from B6SJLF1 mice (Taconic). An expressing transgenic line was interbred with CD19 CRE (Jackson labs, Strain B6.129P2(C)-CD19 tm1(cre)Cgn /J) and with Bim fl/fl mice. 23 Treatment regimens for age-matched mice included (1) intraperitoneal (IP) injection (0.3 ml) of a 3.3% sheep red blood cell (SRBC) suspension in PBS (Cocalico Biologicals, PA) followed by repeat dosing after a two month interval, (2) IP injection (0.5 ml) of pristane (400 mg) monthly for three months, (3) single dose IP SRBC followed by pristane (400 mg IP) one week later, (4) single dose IP SRBC followed by 400 cGy irradiation one week later, and (5) weekly IP SRBC for four months. All animal experiments were approved by and conform to the standards of the Dana-Farber
Cancer Institute Animal Care and Use Committee.
Histology and Immunohistochemistry
Mouse tissues were fixed in 10% formalin for more than 24 hours, passed through 28 The microarray data has been deposited in NCBI's Gene Expression Omnibus 29 and is accessible through GEO Series accession number GSE52214 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52214). Figure 3A and 3B). This difference was mostly due to two young pristane-treated Eμ CycD1 mice, one of which had both an elevated WBC count and enlarged spleen. However, neither of these two mice developed lymphoma, as evaluated by whole body necropsy. For each subgroup, treatment with pristane resulted in increased mediastinal lymphadenopathy (Supplemental Figure 3C ). Figure 4) . Notably, cyclin D1 expression was not a prominent feature of these proliferations, as documented by cyclin D1 immunohistochemistry. were not seen (Supplemental Figure 9D) . Thus, we find that the lymphoma arising in 
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Discussion
In normal lymph nodes, naïve B cells surround the germinal center to form a small rim known as the Mantle zone. 36 As these cells enter the germinal center, they are exposed to antigen, expand rapidly, and the majority of cells die by apoptosis during the process of negative selection. 36 The majority of MCL cases are thought to derive from naïve B cells in the Mantle zone, based on the presence of a restricted immunoglobulin variable heavy chain 37 , evidence of somatic mutations 37 and genetic profiling. 38 Furthermore, the restricted usage of variable heavy chains implies that the malignant transformation may be antigen driven. 37 Within these aberrant cells, a translocation places cyclin D1 under the regulation of the immunoglobulin heavy chain locus, resulting in the overexpression of this cell cycle proliferation gene in B cells. However, the proliferative drive alone may be insufficient to produce MCL, as generating this translocation in mouse models fails to induce the disease. Among the numerous secondary mutations that have been identified in MCL, frequent biallelic deletion of the pro-apoptotic BH3-only protein BIM 5, 6 suggests that antigenic stimulation in the context of both an apoptotic blockade (Bim loss) and proliferative drive (cyclin D1 overexpression) could effectively collaborate to produce MCL (Supplemental Figure 10) .
Biochemical, genetic, and clinical evidence has implicated the BH3-only protein BIM as a candidate tumor suppressor, with loss of Bim expression observed in a wide variety of human cancers. 5, [39] [40] [41] [42] Indeed, this central BCL-2 family regulator of apoptosis would be predicted to have robust tumor suppressor activity based on its breadth of protein interactions. BIM not only binds and inhibits all known anti-apoptotic proteins with high affinity 43, 44 , but also directly interacts with and activates the pro-apoptotic [45] [46] [47] Biallelic deletion of Bim has been reported in up to 40% of MCLs. 6 A second study confirmed the frequent deletion of Bim in MCL, and extended the analysis to reveal silencing of the Bim promoter through hypermethylation of CpG islands in 50-80% of Burkitt lymphomas. 5 Nearly 80% of renal cell carcinomas show loss of Bim expression, which is associated with metastasis and B symptoms. 42 Reduced Bim expression in melanoma correlates with poor 5-year survival 39 , whereas elevated Bim expression in colorectal cancer is associated with more favorable diseasefree and overall survival. 41 Finally, BIM has recently been shown to play an essential role in tyrosine kinase inhibitor-induced apoptosis. For example, inhibition of the MEK-ERK pathway relies on BIM induction for apoptosis of EGFR-mutant non small cell lung cancer (NSCLC) 48 , HER2-amplified breast cancer 48, 49 and BRAF-mutant colorectal cancer and melanoma. 50 Therefore, high Bim expression is associated with longer progression-free survival in EGFR-mutant NSCLC and HER2-positive breast cancer patients treated with tyrosine kinase inhibitors. 48 Conversely, patients with a germline polymorphism in Bim that deletes its BH3 domain exhibit relative tyrosine kinase inhibitor resistance in chronic myelogenous leukemia as well as EGFR-positive NSCLC. 40 Bim null mouse models have yielded a mixture of autoimmune and cancer phenotypes. A subset of Bim -/-mice dies during the embryonic period, while the remaining mice develop a progressive lymphadenopathy and a fatal systemic autoimmune disease. 31 Similarly, transgenic overexpression of the miR-17-92 microRNA cluster, which decreases Bim expression, results in lymphoproliferative disease with autoimmune pathology. 51 Hematopoietic tumors, including diffuse large B 
